{"id":"NCT00124982","sponsor":"Bristol-Myers Squibb","briefTitle":"Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy","officialTitle":"A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-Biologic DMARDs Who Have an Inadequate Response to Anti-TNF Therapy and Have Limited Therapeutic Options","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-04","primaryCompletion":"2009-08","completion":"2009-08","firstPosted":"2005-07-29","resultsPosted":"2011-06-02","lastUpdate":"2012-02-27"},"enrollment":1286,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Abatacept","otherNames":["Orencia"]},{"type":"DRUG","name":"Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)","otherNames":[]},{"type":"DRUG","name":"Anti-Tumor Necrosing Factor (TNF) Therapy","otherNames":[]}],"arms":[{"label":"Open-label Abatacept (ABA)-Previous User","type":"EXPERIMENTAL"},{"label":"Open-label ABA-Current User","type":"EXPERIMENTAL"},{"label":"Long-term ABA","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to summarize the safety and tolerability of abatacept during 6 months of combined treatment with one or more of the background non-biologic disease modifying anti-rheumatic drugs (DMARDs) approved for rheumatoid arthritis (RA) in subjects with active RA. Secondary objectives assessed the clinical efficacy of combination treatment, including disease activity, physical function, and quality of life outcomes.","primaryOutcome":{"measure":"Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations","timeFrame":"Days 1-169","effectByArm":[{"arm":"ST Abatacept (ABA)-Previous User","deltaMin":1,"sd":null},{"arm":"ST ABA-Current User","deltaMin":1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":2},"locations":{"siteCount":148,"countries":["United States","Belgium","Czechia","France","Germany","Ireland","Italy","Mexico","Spain","United Kingdom"]},"refs":{"pmids":["19074911","29329602","27889300","18402714","17921185"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":61,"n":530},"commonTop":["HEADACHE","NAUSEA","UPPER RESPIRATORY TRACT INFECTION","SINUSITIS","DIARRHOEA"]}}